Northpointe Capital LLC boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.0% during the first quarter, Holdings Channel reports. The fund owned 139,170 shares of the biopharmaceutical company’s stock after buying an additional 49 shares during the period. Northpointe Capital LLC’s holdings in Pfizer were worth $4,761,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Pfizer during the fourth quarter valued at approximately $1,896,890,000. Asset Management One Co. Ltd. boosted its position in shares of Pfizer by 618.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,094,592 shares of the biopharmaceutical company’s stock valued at $360,362,000 after buying an additional 9,550,335 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in shares of Pfizer during the fourth quarter valued at approximately $289,666,000. Appaloosa LP bought a new position in shares of Pfizer during the fourth quarter valued at approximately $156,229,000. Finally, I.G. Investment Management LTD. boosted its position in shares of Pfizer by 24.7% in the fourth quarter. I.G. Investment Management LTD. now owns 11,087,884 shares of the biopharmaceutical company’s stock valued at $360,134,000 after buying an additional 2,194,738 shares during the last quarter. 69.95% of the stock is owned by institutional investors.
Pfizer, Inc. (NYSE:PFE) opened at 33.54 on Friday. The firm has a market cap of $200.16 billion, a price-to-earnings ratio of 28.23 and a beta of 1.01. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $37.39. The company’s 50 day moving average is $33.20 and its 200-day moving average is $33.25. Pfizer also saw unusually large options trading activity on Tuesday. Investors acquired 21,983 put options on the company. This is an increase of 351% compared to the average daily volume of 4,871 put options.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The company had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. During the same period in the previous year, the firm posted $0.67 earnings per share. The company’s revenue was down 1.7% on a year-over-year basis. On average, analysts predict that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.82%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 108.48%.
WARNING: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/07/21/northpointe-capital-llc-has-4-76-million-position-in-pfizer-inc-nysepfe.html.
Several brokerages have recently commented on PFE. Jefferies Group LLC reaffirmed a “hold” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Friday, July 14th. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday. BidaskClub cut shares of Pfizer from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $36.00 in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $37.68.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.